Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Locations: - Banner University Medical Center - Tucson — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
+ 253 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer th…
Sponsor: NRG Oncology
NCT ID: NCT04804644
Locations: - Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Bellflower — Bellflower, California
+ 220 more sites in the U.S.
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Locations: - Children's Hospital of Alabama — Birmingham, Alabama
- Banner Children's at Desert — Mesa, Arizona
- Phoenix Childrens Hospital — Phoenix, Arizona
+ 121 more sites in the U.S.
Phase 3 Recruiting Industry
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Locations: - Banner MD Anderson Cancer Center — Phoenix, Arizona
- Barrow Neurological Institute — Phoenix, Arizona
- Phoenix Childrens Hospital — Phoenix, Arizona
+ 64 more sites in the U.S.
Phase 2, Phase 3 Recruiting Academic/Other
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …
Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Locations: - University of Alabama at Birmingham — Birmingham, Alabama
- University of California, San Diego — La Jolla, California
- Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute — Los Angeles, California
+ 39 more sites in the U.S.
Phase 3 Recruiting Industry
This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade g…
Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT05566795
Locations: - Children's of Alabama — Birmingham, Alabama
- Phoenix Children's Hospital — Phoenix, Arizona
- Children's Hospital Los Angeles — Los Angeles, California
+ 35 more sites in the U.S.
Phase 3 Recruiting Industry
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…
Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Locations: - Mayo Clinic Hospital — Phoenix, Arizona
- University of Southern California — Los Angeles, California
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
+ 27 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
Sponsor: Hoffmann-La Roche
NCT ID: NCT05503264
Locations: - University of Alabama at Birmingham — Birmingham, Alabama
- UC San Diego — La Jolla, California
- Hoag Memorial Hospital — Newport Beach, California
+ 17 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…
Sponsor: InSightec
NCT ID: NCT05317858
Locations: - St. Joseph's Hospital and Medical Center — Phoenix, Arizona
- Miami Cancer Institute at Baptist Health — Miami, Florida
- Moffitt Cancer Center — Tampa, Florida
+ 5 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects and how well stereotactic radiosurgery (SRS) works before or after surgery in patients with tumors that has spread to the brain or that can be removed by surgery. Stereotactic radiosurgery is a…
Sponsor: Mayo Clinic
NCT ID: NCT03750227
Locations: - Mayo Clinic in Arizona — Scottsdale, Arizona
- Mayo Clinic in Florida — Jacksonville, Florida
- National Institutes of Neurological Disorders and Stroke, NIH — Bethesda, Maryland
+ 1 more site in the U.S.
Phase 3 Recruiting Industry
This is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows: * A Screening/Baseline Period of 21 days. During this time, patients will be randomized into a 1:2 allocation o…
Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT07195591
Locations: - HMH Jersey Shore University Medical Center — Neptune City, New Jersey
- Westchester Medical Center — Valhalla, New York
- Brown University Health — Providence, Rhode Island
Phase 3 Recruiting Academic/Other
Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the…
Sponsor: Northwell Health
NCT ID: NCT05271240
Locations: - Lenox Hill Brain Tumor Center — New York, New York